
Orphazyme, a listed company in Denmark that has been restructuring since March, has postponed its annual report for 2021 yet again, a company press release states.
This follows the Sunday announcement that the Danish firm has come to a binding agreement with US-based Kempharm, entailing the sale of all substantial Orphazyme assets and business activities.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app